Research Topics
| D M MooreSummaryAffiliation: British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Implications for HIV prevention programs from a serobehavioural survey of men who have sex with men in Vancouver, British Columbia: the ManCount studyDavid M Moore
British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC
Can J Public Health 103:142-6. 2012..We examined HIV prevalence, awareness of HIV serostatus and HIV risk behaviour among a sample of men who have sex with men (MSM) in Vancouver...- Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural UgandaDavid Moore
Global AIDS Program, Us centers for Disease Control and Prevention CDC, Entebbe, Uganda
AIDS 21:713-9. 2007..Tuberculosis (TB) is the leading cause of death among people with HIV in sub-Saharan Africa. Expanding access to antiretroviral therapy (ART) may reduce the burden of TB, but to what extent is unknown... 
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapyDavid M Moore
Global AIDS Program, US Centers for Disease Control and Prevention, Entebbe, Uganda
J Acquir Immune Defic Syndr 49:477-84. 2008..However, the utility of such monitoring in terms of predicting virologic response to therapy has been little studied...- Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settingsDavid M Moore
British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
J Acquir Immune Defic Syndr 43:436-9. 2006..The performance of immunologic monitoring for this purpose has not been evaluated, however... - Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapyD M Moore
BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
HIV Med 7:311-6. 2006.... - CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microLD M Moore
BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
HIV Med 7:383-8. 2006..To determine the prognostic value of baseline CD4 percentage in terms of patient survival in comparison to absolute CD4 cell counts for HIV-positive patients initiating highly active antiretroviral therapy (HAART)... 
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppressionDavid M Moore
Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
J Acquir Immune Defic Syndr 52:357-63. 2009..However, the effects of immunologic responses, whether measured as CD4 count changes from baseline or CD4 counts at follow-up, in patients with virologic suppression, have not been clearly established...- Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapyDavid M Moore
BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
Antivir Ther 11:125-9. 2006..We designed a study to determine whether risks for later mortality are similar for HCV-positive and HCV-negative individuals when subjects are stratified on the basis of baseline CD4+ T-cell counts... - Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological responseDavid M Moore
BC Centre for Excellence in HIV AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
AIDS 20:371-7. 2006..To determine if immunological response is associated with disease progression in patients with virological suppression after initiating HAART... - Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programmeD M Moore
British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
HIV Med 11:299-307. 2010..We examined clinical outcomes, patient characteristics and trends over time of non-medically supervised treatment interruptions (TIs) from a free-of-charge antiretroviral therapy (ART) programme in British Columbia (BC), Canada... - Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapyDavid M Moore
British Columbia Centre for Excellence in HIV AIDS, 608 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
J Acquir Immune Defic Syndr 40:288-93. 2005..To examine the independent association of discordant virologic and immunologic responses to highly active antiretroviral therapy (HAART) with mortality... - Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural UgandaDavid M Moore
Global AIDS Program, Us centers for Disease Control and Prevention CDC, Entebbe, Uganda
J Acquir Immune Defic Syndr 58:289-96. 2011..Understanding the clinical conditions associated with mortality could potentially lead to effective interventions to prevent these deaths... - Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational studySiavash Jafari
British Columbia Centre for Excellence in HIV AIDS, St, Paul s Hospital, Vancouver, Canada
AIDS Res Ther 8:31. 2011..abstract:.. - Protecting health care workers from SARS and other respiratory pathogens: organizational and individual factors that affect adherence to infection control guidelinesDavid Moore
Occupational Health and Safety Agency for Healthcare in British Columbia, Canada
Am J Infect Control 33:88-96. 2005.... - Monitoring antiretroviral failure in resource-poor settingsDavid M Moore
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, V6T 1Y6
Lancet 371:1396-7. 2008 - The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysisM Murray
Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada
HIV Med 13:89-97. 2012..We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non-IDUs who initiate combination antiretroviral therapy (cART)... - Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment programPaula Braitstein
British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
J Infect Dis 193:259-68. 2006..We sought to characterize the impact that hepatitis C virus (HCV) infection has on CD4 cells during the first 48 weeks of antiretroviral therapy (ART) in previously ART-naive human immunodeficiency virus (HIV)-infected patients... - Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microlEvan Wood
British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, 667-1081 Burrard Street, Vancouver, BC, Canada
AIDS 20:1117-23. 2006..89-1.65; P = 0.232). CONCLUSION: HIV RNA > or = 100 000 copies/ml was only associated with mortality among HIV-infected patients initiating HAART with CD4 cell counts > or= 200 cells/microl if the patients were non-adherent... - A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facilityThomas Kerr
British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
Int J Drug Policy 18:37-45. 2007..Safer injection facilities (SIFs) constitute one such intervention, although little is known about the impact of such facilities on factors that mediate risk for overdose... - Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapyViviane D Lima
BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
AIDS 21:685-92. 2007..To characterize the temporal changes in mortality and life expectancy among HIV-positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to 2004... - Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literatureBruce Gamage
British Columbia Centre for Disease Control, Vancouver, BC, Canada
Am J Infect Control 33:114-21. 2005..SARS focused attention on the adequacy of and compliance with infection control practices in preventing airborne and droplet-spread transmission of infectious agents... - Back to work: correlates of employment among persons receiving highly active antiretroviral therapyMarcus Lem
University of British Columbia, Canada
AIDS Care 17:740-6. 2005..In conclusion, our study demonstrates that while significant advances have been made in the reduction of HIV-related mortality, the majority of HIV-infected individuals on adequate treatment are still unable to be gainfully employed... - Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort studyJaco Homsy
Centers for Disease Control and Prevention, Global AIDS Program, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Entebbe, Uganda
PLoS ONE 4:e4149. 2009.... - Total lymphocyte counts and ART in resource-limited settingsDavid Moore
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada V6Z 1Y6
Lancet 366:1831-2. 2005 - Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort studyJonathan Mermin
Centers for Disease Control and Prevention Uganda, Global AIDS Program, National Center for HIV, Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Entebbe, Uganda
Lancet 371:752-9. 2008..We therefore assessed the effect of a home-based ART programme in Uganda on mortality, hospital admissions, and orphanhood in people with HIV-1 and their household members... - Two-year follow-up of sexual behavior among HIV-uninfected household members of adults taking antiretroviral therapy in Uganda: no evidence of disinhibitionStevens Bechange
CDC Uganda, Global AIDS Program, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Uganda Virus Research Institute, Centers for Disease Control and Prevention CDC, Entebbe, Uganda
AIDS Behav 14:816-23. 2010..No evidence of behavioral disinhibition was observed. Concerns regarding behavioral disinhibition should not slow down efforts to increase ART access in Africa... - Trends in antenatal human immunodeficiency virus prevalence in Western Kenya and Eastern Uganda: evidence of differences in health policies?David M Moore
Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada
Int J Epidemiol 33:542-8. 2004..Design An ecologic study was conducted at the district level comparing HIV prevalence rates over time using data available through reports published by the Kenyan and Ugandan Ministries of Health and UNAIDS... - Occupational health and infection control practices related to severe acute respiratory syndrome: health care worker perceptionsDavid M Moore
Occupational Health and Safety Agency for Health Care in British Columbia, Vancouver, British Columbia, Canada
AAOHN J 53:257-66. 2005.... - Antiretroviral therapy improves renal function among HIV-infected UgandansPhilip J Peters
Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Kidney Int 74:925-9. 2008..Our study shows that renal dysfunction was common with advanced HIV disease in Uganda but this improved following 2 years of HAART...